{"id":"NCT01455194","sponsor":"AstraZeneca","briefTitle":"Effect of High Dose Ciclesonide on Asthma Control","officialTitle":"Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2011-10-19","resultsPosted":"2016-10-25","lastUpdate":"2017-02-10"},"enrollment":520,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bronchial Asthma"],"interventions":[{"type":"DRUG","name":"Ciclesonide","otherNames":[]}],"arms":[{"label":"CIC 160","type":"ACTIVE_COMPARATOR"},{"label":"CIC 320","type":"ACTIVE_COMPARATOR"},{"label":"CIC 640","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).","primaryOutcome":{"measure":"Asthma Control Questionnaire (ACQ) Score at Baseline","timeFrame":"Baseline","effectByArm":[{"arm":"Treatment Period: Ciclesonide 160 mcg","deltaMin":2.24,"sd":0.031},{"arm":"Treatment Period: Ciclesonide 320 mcg","deltaMin":2.15,"sd":0.035},{"arm":"Treatment Period: Ciclesonide 640 mcg","deltaMin":2.19,"sd":0.032}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":30,"countries":["Argentina","Brazil","Germany","Israel","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":520},"commonTop":["Headache","Nasopharyngitis","Bronchitis","Influenza","Sinusitis"]}}